StreetInsider.com News Articles

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jun 18

Fri, 29 May 2026 14:18:00 -0400

si-local-file:///var/storage/secattach/20260529/26573747.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jun 18

Fri, 29 May 2026 14:18:00 -0400

si-local-file:///var/storage/secattach/20260529/26573747.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: May 28

Fri, 29 May 2026 14:10:00 -0400

si-local-file:///var/storage/secattach/20260529/26573677.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: May 28

Fri, 29 May 2026 14:10:00 -0400

si-local-file:///var/storage/secattach/20260529/26573677.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: May 28

Thu, 28 May 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260528/26567804.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: May 28

Thu, 28 May 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260528/26567804.html

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company’s management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026.

Jefferies Global Healthcare Conference
1x1 Meetings: June 3^rd and 4^th
Presentation Date & Time: June 3^rd, 2026, at 5:30PM – 6:00PM ET
Location: New York, NY
Webcast registration link: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/8dAzVtF9jmoLFUYwXokBzq

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

Stifel Starts Eupraxia Pharmaceuticals (EPRX) at Buy

Wed, 20 May 2026 16:06:43 -0400

Stifel analyst Samimy Annabel initiates coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX) with a Buy rating and a price target of $25.00.

The analyst comments "We initiate coverage of Eupraxia Pharma (EPRX) with a Buy rating, $25 TP. On the back of its Diffusphere platform, Eupraxia is finding a solution to an age-old problem—delivering effective therapies to a precise target, in a precise amount, over long duration—and offering meaningful clinical benefit (efficacy, tolerability, simplicity) for poorly-served conditions. Eupraxia is validating this platform starting with a well-known corticosteroid, fluticasone propionate, for various GI conditions, namely eosinophilic esophagitis/EoE—where the anti-inflammatory/anti-fibrotic MoA has been well-established.

Stifel Starts Eupraxia Pharmaceuticals (EPRX) at Buy

Wed, 20 May 2026 16:06:43 -0400

Stifel analyst Samimy Annabel initiates coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX) with a Buy rating and a price target of $25.00.

Stifel Starts Eupraxia Pharmaceuticals (EPRX) at Buy

Wed, 20 May 2026 16:06:43 -0400

Stifel analyst Samimy Annabel initiates coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX) with a Buy rating and a price target of $25.00.

Stifel Starts Eupraxia Pharmaceuticals (EPRX) at Buy

Wed, 20 May 2026 16:06:43 -0400

Stifel analyst Samimy Annabel initiates coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX) with a Buy rating and a price target of $25.00.

Form SCHEDULE 13G/A EUPRAXIA PHARMACEUTICALS Filed by: MANCHESTER MANAGEMENT CO LLC

Tue, 12 May 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260512/26479794.html

Form SCHEDULE 13G/A EUPRAXIA PHARMACEUTICALS Filed by: MANCHESTER MANAGEMENT CO LLC

Tue, 12 May 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260512/26479794.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: May 12

Tue, 12 May 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260512/26479211.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: May 12

Tue, 12 May 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260512/26479211.html

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 17:00:00 -0400

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI

Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications

Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash

VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the first

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 17:00:00 -0400

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI

Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications

Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash

Eupraxia Pharmaceuticals reports tissue improvements in EoE trial

Wed, 06 May 2026 07:00:45 -0400

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) (TSX: EPRX) reported data from its ongoing Phase 1b/2a RESOLVE trial showing improvements in esophageal tissue inflammation and fibrosis in patients with eosinophilic esophagitis. The company presented the findings at the Digestive Disease Week conference in Chicago.

The data measured EoEHSS sub scores, which evaluate tissue inflammation and architecture in the esophagus. Results showed improvements in inflammation scores across all reported patient cohorts at both 12 weeks and 36 weeks. Tissue architecture scores, which measure fibrosis, demonstrated improvements across most cohorts at both time points.

The trial tested EP-104GI at various doses delivered through esophageal wall injections.

Eupraxia Pharmaceuticals reports tissue improvements in EoE trial

Wed, 06 May 2026 07:00:45 -0400

The trial tested EP-104GI at various doses delivered through esophageal wall injections.

Eupraxia Pharmaceuticals reports tissue improvements in EoE trial

Wed, 06 May 2026 07:00:45 -0400

The trial tested EP-104GI at various doses delivered through esophageal wall injections.

Eupraxia Pharmaceuticals reports tissue improvements in EoE trial

Wed, 06 May 2026 07:00:45 -0400

The trial tested EP-104GI at various doses delivered through esophageal wall injections.

Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Wed, 06 May 2026 07:00:00 -0400

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue architecture (which is a measure of fibrosis)
EoEHSS sub scores for inflammation demonstrated improvements in all reported cohorts at both 12 weeks (n=31) and 36 weeks (n=27)
EoEHSS sub scores for tissue architecture (fibrosis) demonstrated improvements across most reported cohorts at 12 and 36 weeks
The largest response in both the inflammatory and the architectural (fibrosis) sub scores was seen at the highest dose tested

Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Wed, 06 May 2026 07:00:00 -0400

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue architecture (which is a measure of fibrosis)
EoEHSS sub scores for inflammation demonstrated improvements in all reported cohorts at both 12 weeks (n=31) and 36 weeks (n=27)
EoEHSS sub scores for tissue architecture (fibrosis) demonstrated improvements across most reported cohorts at 12 and 36 weeks
The largest response in both the inflammatory and the architectural (fibrosis) sub scores was seen at the highest dose tested

Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Wed, 06 May 2026 07:00:00 -0400

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue architecture (which is a measure of fibrosis)
EoEHSS sub scores for inflammation demonstrated improvements in all reported cohorts at both 12 weeks (n=31) and 36 weeks (n=27)
EoEHSS sub scores for tissue architecture (fibrosis) demonstrated improvements across most reported cohorts at 12 and 36 weeks
The largest response in both the inflammatory and the architectural (fibrosis) sub scores was seen at the highest dose tested